ARTICLE | Product Development
Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight
COVID-19 has lit a path to greater data sharing
September 10, 2020 1:15 AM UTC
This is the third article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development.
Biopharma companies have come together to share data in COVID-19 because they believe that getting data out fast and wide is the best way to expedite development. ...